{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T18:37:47Z","timestamp":1760985467880,"version":"3.41.2"},"reference-count":19,"publisher":"American Academy of Pediatrics (AAP)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,9,1]]},"abstract":"<jats:title>This Policy Statement was retired March 2021.<\/jats:title>\n               <jats:p>This policy statement provides recommendations for the prevention of serogroup B meningococcal disease through the use of 2 newly licensed serogroup B meningococcal vaccines: MenB-FHbp (Trumenba; Wyeth Pharmaceuticals, a subsidiary of Pfizer, Philadelphia, PA) and MenB-4C (Bexsero; Novartis Vaccines, Siena, Italy). Both vaccines are approved for use in persons 10 through 25 years of age. MenB-FHbp is licensed as a 2- or 3-dose series, and MenB-4C is licensed as a 2-dose series for all groups. Either vaccine is recommended for routine use in persons 10 years and older who are at increased risk of serogroup B meningococcal disease (category A recommendation). Persons at increased risk of meningococcal serogroup B disease include the following: (1) persons with persistent complement component diseases, including inherited or chronic deficiencies in C3, C5\u2013C9, properdin, factor D, or factor H or persons receiving eculizumab (Soliris; Alexion Pharmaceuticals, Cheshire, CT), a monoclonal antibody that acts as a terminal complement inhibitor by binding C5 and inhibiting cleavage of C5 to C5A; (2) persons with anatomic or functional asplenia, including sickle cell disease; and (3) healthy persons at increased risk because of a serogroup B meningococcal disease outbreak. Both serogroup B meningococcal vaccines have been shown to be safe and immunogenic and are licensed by the US Food and Drug Administration for individuals between the ages of 10 and 25 years. On the basis of epidemiologic and antibody persistence data, the American Academy of Pediatrics agrees with the Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention that either vaccine may be administered to healthy adolescents and young adults 16 through 23 years of age (preferred ages are 16 through 18 years) to provide short-term protection against most strains of serogroup B meningococcal disease (category B recommendation).<\/jats:p>","DOI":"10.1542\/peds.2016-1890","type":"journal-article","created":{"date-parts":[[2016,8,29]],"date-time":"2016-08-29T09:07:25Z","timestamp":1472461645000},"source":"Crossref","is-referenced-by-count":30,"title":["Recommendations for Serogroup B Meningococcal Vaccine for Persons 10 Years and Older"],"prefix":"10.1542","volume":"138","author":[{"name":"COMMITTEE ON INFECTIOUS DISEASES","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carrie L.","family":"Byington","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yvonne A.","family":"Maldonado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth D.","family":"Barnett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. Dele","family":"Davies","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathryn M.","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruth","family":"Lynfield","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Flor M.","family":"Munoz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dawn L.","family":"Nolt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann-Christine","family":"Nyquist","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mobeen H.","family":"Rathore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark H.","family":"Sawyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William J.","family":"Steinbach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tina Q.","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theoklis E.","family":"Zaoutis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"417","published-online":{"date-parts":[[2016,9,1]]},"reference":[{"key":"2023092515011722700_B1","first-page":"1","article-title":"Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP).","volume":"62","author":"Cohn","year":"2013","journal-title":"MMWR Recomm Rep"},{"key":"2023092515011722700_B2","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/j.1365-2249.1991.tb06209.x","article-title":"Complement deficiencies and meningococcal disease.","volume":"86","author":"Densen","year":"1991","journal-title":"Clin Exp Immunol"},{"key":"2023092515011722700_B3","unstructured":"Alexion Pharmaceuticals\n          . Soliris [package insert]. Cheshire, CT: Alexion Pharmaceuticals, Inc; April 2014. Available at: http:\/\/soliris.net\/sites\/default\/files\/assets\/soliris_pi.pdf. Accessed January 21, 2016"},{"issue":"1","key":"2023092515011722700_B4","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1128\/IAI.72.1.332-337.2004","article-title":"Immune response to meningococcal serogroup C conjugate vaccine in asplenic individuals.","volume":"72","author":"Balmer","year":"2004","journal-title":"Infect Immun"},{"key":"2023092515011722700_B5","unstructured":"Centers for Disease Control and Prevention\n          . Interim guidance for control of serogroup B meningococcal disease outbreaks in organizational settings. Available at: www.cdc.gov\/meningococcal\/downloads\/interim-guidance.pdf. Accessed January 21, 2016"},{"issue":"8346","key":"2023092515011722700_B6","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0140-6736(83)90340-9","article-title":"Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis.","volume":"2","author":"Finne","year":"1983","journal-title":"Lancet"},{"issue":"9816","key":"2023092515011722700_B7","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S0140-6736(11)61713-3","article-title":"Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b\/3 randomised, observer-blind, placebo-controlled study.","volume":"379","author":"Santolaya","year":"2012","journal-title":"Lancet"},{"issue":"11","key":"2023092515011722700_B8","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.4161\/hv.25505","article-title":"Persistence of antibodies in adolescents 18-24 months after immunization with one, two, or three doses of 4CMenB meningococcal serogroup B vaccine.","volume":"9","author":"Santolaya","year":"2013","journal-title":"Hum Vaccin Immunother"},{"issue":"3","key":"2023092515011722700_B9","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1128\/CVI.00304-10","article-title":"Immunogenicity and safety of a multicomponent meningococcal serogroup B vaccine and a quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135, and Y in adults who are at increased risk for occupational exposure to meningococcal isolates.","volume":"18","author":"Kimura","year":"2011","journal-title":"Clin Vaccine Immunol"},{"issue":"9960","key":"2023092515011722700_B10","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1016\/S0140-6736(14)60842-4","article-title":"Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial.","volume":"384","author":"Read","year":"2014","journal-title":"Lancet"},{"key":"2023092515011722700_B11","unstructured":"Block\u2008SL, Szenborn\u2008L, Daly\u2008W, et al. Comparative evaluation of two different investigational meningococcal ABCWY vaccine formulations in adolescents and young adults. Presented at: Infectious Disease Week; October 8\u201312, 2014; Philadelphia, PA. Available at: https:\/\/idsa.confex.com\/idsa\/2014\/webprogram\/Paper46007.html. Accessed January 21, 2016"},{"issue":"6","key":"2023092515011722700_B12","doi-asserted-by":"crossref","first-page":"646","DOI":"10.4161\/hv.7.6.15482","article-title":"The first use of an investigational multicomponent meningococcal serogroup B vaccine (4CMenB) in humans.","volume":"7","author":"Toneatto","year":"2011","journal-title":"Hum Vaccin"},{"issue":"12","key":"2023092515011722700_B13","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/j.vaccine.2013.01.021","article-title":"A phase 2 open-label safety and immunogenicity study of a meningococcal B bivalent rLP2086 vaccine in healthy adults.","volume":"31","author":"Marshall","year":"2013","journal-title":"Vaccine"},{"issue":"7","key":"2023092515011722700_B14","doi-asserted-by":"crossref","first-page":"888","DOI":"10.4161\/hv.19983","article-title":"A phase 1, randomized, open-label, active-controlled trial to assess the safety of a meningococcal serogroup B bivalent rLP2086 vaccine in healthy adults.","volume":"8","author":"Sheldon","year":"2012","journal-title":"Hum Vaccin Immunother"},{"issue":"8","key":"2023092515011722700_B15","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S1473-3099(12)70087-7","article-title":"Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial.","volume":"12","author":"Richmond","year":"2012","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"2023092515011722700_B16","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1097\/INF.0000000000001072","article-title":"Immunogenicity, tolerability and safety in adolescents of bivalent rLP2086, a meningococcal serogroup B vaccine, coadministered with quadrivalent human papilloma virus vaccine.","volume":"35","author":"Senders","year":"2016","journal-title":"J Clin Infect Dis"},{"issue":"5","key":"2023092515011722700_B17","doi-asserted-by":"crossref","first-page":"e01625","DOI":"10.1128\/mBio.01625-14","article-title":"Human factor H (FH) impairs protective meningococcal anti-FHbp antibody responses and the antibodies enhance FH binding.","volume":"5","author":"Costa","year":"2014","journal-title":"MBio"},{"issue":"5","key":"2023092515011722700_B18","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1542\/peds.2004-2514","article-title":"Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States.","volume":"115","author":"MacNeil","year":"2005","journal-title":"Pediatrics"},{"issue":"41","key":"2023092515011722700_B19","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.15585\/mmwr.mm6441a3","article-title":"Use of serogroup B meningococcal vaccines in adolescents and young adults: recommendations of the Advisory Committee on Immunization Practices, 2015.","volume":"64","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2016-1890\/1531566\/peds_20161890.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2016-1890\/1531566\/peds_20161890.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T15:01:56Z","timestamp":1695654116000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/138\/3\/e20161890\/52662\/Recommendations-for-Serogroup-B-Meningococcal"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,1]]},"references-count":19,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2016,9,1]]},"published-print":{"date-parts":[[2016,9,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2016-1890","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"type":"print","value":"0031-4005"},{"type":"electronic","value":"1098-4275"}],"subject":[],"published":{"date-parts":[[2016,9,1]]},"article-number":"e20161890"}}